120 related articles for article (PubMed ID: 17159600)
1. Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.
Lewis LJ; Mistry P; Charlton PA; Thomas H; Coley HM
Anticancer Drugs; 2007 Feb; 18(2):139-48. PubMed ID: 17159600
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
3. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
Jobson AG; Willmore E; Tilby MJ; Mistry P; Charlton P; Austin CA
Cancer Chemother Pharmacol; 2009 Apr; 63(5):889-901. PubMed ID: 18679685
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576.
Wang S; Miller W; Milton J; Vicker N; Stewart A; Charlton P; Mistry P; Hardick D; Denny WA
Bioorg Med Chem Lett; 2002 Feb; 12(3):415-8. PubMed ID: 11814810
[TBL] [Abstract][Full Text] [Related]
6. Biological characterization of MLN944: a potent DNA binding agent.
Sappal DS; McClendon AK; Fleming JA; Thoroddsen V; Connolly K; Reimer C; Blackman RK; Bulawa CE; Osheroff N; Charlton P; Rudolph-Owen LA
Mol Cancer Ther; 2004 Jan; 3(1):47-58. PubMed ID: 14749475
[TBL] [Abstract][Full Text] [Related]
7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
8. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Vanhuyse M; Kluza J; Tardy C; Otero G; Cuevas C; Bailly C; Lansiaux A
Cancer Lett; 2005 Apr; 221(2):165-75. PubMed ID: 15808402
[TBL] [Abstract][Full Text] [Related]
9. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Vicker N; Burgess L; Chuckowree IS; Dodd R; Folkes AJ; Hardick DJ; Hancox TC; Miller W; Milton J; Sohal S; Wang S; Wren SP; Charlton PA; Dangerfield W; Liddle C; Mistry P; Stewart AJ; Denny WA
J Med Chem; 2002 Jan; 45(3):721-39. PubMed ID: 11806724
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
11. Fused aryl-phenazines: scaffold for the development of bioactive molecules.
Moorthy NS; Pratheepa V; Ramos MJ; Vasconcelos V; Fernandes PA
Curr Drug Targets; 2014; 15(7):681-8. PubMed ID: 24499398
[TBL] [Abstract][Full Text] [Related]
12. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
13. XR5944: A potent inhibitor of estrogen receptors.
Punchihewa C; De Alba A; Sidell N; Yang D
Mol Cancer Ther; 2007 Jan; 6(1):213-9. PubMed ID: 17218634
[TBL] [Abstract][Full Text] [Related]
14. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Sharma S; Charlton PA; Norris D; Cree IA
Mol Cancer Ther; 2004 Dec; 3(12):1631-7. PubMed ID: 15634657
[TBL] [Abstract][Full Text] [Related]
15. Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
Herzog CE; Zwelling LA; McWatters A; Kleinerman ES
Clin Cancer Res; 1995 Nov; 1(11):1391-7. PubMed ID: 9815936
[TBL] [Abstract][Full Text] [Related]
16. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Harris SM; Mistry P; Freathy C; Brown JL; Charlton PA
Br J Cancer; 2005 Feb; 92(4):722-8. PubMed ID: 15700035
[TBL] [Abstract][Full Text] [Related]
18. DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.
Lin C; Yang D
Curr Top Med Chem; 2015; 15(14):1385-97. PubMed ID: 25866279
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
20. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
